Eliem Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(56,586) | $(27,510) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 977 | 10,948 |
| Right-of-use asset impairment | — | 180 |
| Non-cash operating lease expense | 178 | 232 |
| Accretion of discounts and amortization of premiums on investments, net | (63) | (1,232) |
| In-process research and development, related party | 51,659 | — |
| Foreign currency (gain) loss from remeasurement | 9 | (630) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 2,425 | (784) |
| Long-term assets | 15 | (1,528) |
| Accounts payable | (1,160) | 128 |
| Accounts payable and accrued liabilities, related party | 5 | — |
| Accrued liabilities | 326 | (2,792) |
| Operating lease liabilities | (249) | (209) |
| Long-term liabilities | (22) | 55 |
| Net cash used in operating activities | $(2,486) | $(23,142) |
| Cash flows from investing activities: | ||
| Issuance of promissory loan in connection with asset acquisition | (5,000) | — |
| Cash paid in connection with asset acquisition, net of cash acquired | (4,645) | — |
| Purchase of marketable securities | — | (55,985) |
| Proceeds from maturities of marketable securities | 13,751 | 60,181 |
| Net cash provided by investing activities | $4,106 | $4,196 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in private placement, net of issuance costs | 119,750 | — |
| Proceeds from the exercise of stock options | 8,667 | 25 |
| Net cash provided by financing activities | $128,417 | $25 |
| Effect of exchange rate changes on cash and cash equivalents | (9) | 630 |
| Net change in cash and cash equivalents | $130,028 | $(18,291) |
| Cash and cash equivalents at beginning of period | 93,112 | 43,585 |
| Cash and cash equivalents at end of period | $223,140 | $25,294 |
| Supplemental disclosure of cash operating activities: | ||
| Cash paid for leases included in operating cash outflows | $263 | $244 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Issuance of common stock in exchange for in-process research and development | $41,867 | $— |
| Settlement of promissory loan in connection with asset acquisition | $5,036 | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $— | $313 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.